Jaime da Silva Arocho
Nephrology · Aguailia, PRNPI 1720062144
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.
Across 57 payments — averaging $67.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nxstage Medical, Inc.$920
- AstraZeneca$723
- Fresenius USA Marketing, Inc.$324
- Amgen$299
- Boehringer Ingelheim$250
- Bayer$203
- plus $1K from 12 others
What the payments were for
- Food & beverage$3,838100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nxstage Medical, Inc. | 7 | $920 |
| AstraZeneca | 21 | $723 |
| Fresenius USA Marketing, Inc. | 3 | $324 |
| Amgen(2 entities) | 3 | $299 |
| Boehringer Ingelheim | 2 | $250 |
| Bayer | 4 | $203 |
| Calliditas Therapeutics US Inc. | 2 | $198 |
| Medtronic | 1 | $127 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 2 | $117 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $117 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $115 |
| Travere Therapeutics, Inc. | 1 | $108 |
| Boston Scientific | 1 | $83 |
| Johnson & Johnson | 2 | $75 |
| Lilly USA, LLC | 1 | $26 |
| Bayer Puerto Rico Inc. | 1 | $23 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$778
- LIBERTY SELECT CYCLER$341
- KRYSTEXXA$250
- JARDIANCE$250
- 2008T BLUESTAR HEMODIALYSIS MACHINE$186
- 2008K @ Home$186
- ELLIPSYS VASCULAR ACCESS SYSTEM$127
- JYNARQUE$125
- Kerendia$125
- LOKELMA$124
- TARPEYO$120
- FARXIGA$118
How this compares
$3,847 in reported general payments places this provider in the 80th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 325 | $206,261 |
| Sevelamer Carbonate | 347 | $57,653 |
| Lanthanum Carbonate | 50 | $34,422 |
| EliquisApixaban | 36 | $19,373 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $17,890 |
| Calcium Acetate | 152 | $13,768 |
| RetacritEpoetin Alfa-Epbx | 18 | $8,444 |
| LantusInsulin Glargine,hum.Rec.Anlog | 88 | $7,580 |
| JardianceEmpagliflozin | 11 | $6,834 |
| Sodium Polystyrene Sulfonate | 48 | $4,911 |
| HumalogInsulin Lispro | 54 | $3,818 |
| Cinacalcet Hcl | 45 | $3,037 |
| Losartan Potassium | 395 | $2,648 |
| Potassium Citrate ErPotassium Citrate | 28 | $2,255 |
| Calcitriol | 167 | $1,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $723 | $224,151359 claims |
| Boehringer IngelheimJardiance | $250 | $6,83411 claims |
| Lilly USA, LLCHumalog | $26 | $3,81854 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Aguailia
- Eddie Rodriguez CastroToa Baja$591K
- William Hurtado-SantiagoMayaguez$191K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
- Antonio JimenezGuaynabo$16K
- Cesar Hernandez-ArroyoTrujillo Alto$13K
- Stephanie Colon-LopezBayamon$13K
- Pedro ColtonSanturce$12K
- Rafael Burgos CalderonBayamon$12K
- Angel Rivera SantosPonce$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.